Since the first description of video-assisted thoracic surgery (VATS) for early stage non-small cell lung cancer (NSCLC) was published in the early 1990s, two small randomized, controlled trials (RCT) and a number of case series studies have reported improved perioperative outcomes and similar long-term survival outcomes compared with open thoracotomy.
Since the first description of video-assisted thoracic surgery (VATS) for early stage non-small cell lung cancer (NSCLC) was published in the early 1990s, two small randomized, controlled trials (RCT) and a number of case series studies have reported improved perioperative outcomes and similar long-term survival outcomes compared with open thoracotomy. [1] [2] [3] Despite these encouraging results, VATS continue to represent only a minority of procedures performed for patients with NSCLC worldwide. A number of reasons may account for the lack of popularization of the VATS technique, such as lack of experience and training in some centres, concerns about its safety profile, and uncertainty about its long-term oncologic efficacy.
Hennon et al. presented a retrospective study involving 114 patients with NSCLC who underwent VATS (n = 95) or open thoracotomy (n = 19). 4 The conversion rate for patients intended for VATS was 23%, which is relatively high compared with the current literature. 1 Air leak was reported in 18% of patients who underwent VATS, which also is higher than most other reports. However, the authors highlighted a relatively large proportion of patients with advanced-stage NSCLC in their VATS cohort; more than 20% of patients were diagnosed with pathologic stage III or IV disease. Perioperative outcomes were similar between the two groups, but results should be interpreted with caution due to the relatively few patients in the open thoracotomy arm. Overall and disease-free survival outcomes also were similar between the two groups, but follow-up data was not well described. As expected, a learning curve was evident during a period of 5 years.
Overall, this study was important in demonstrating the feasibility of performing VATS for patients with advancedstage NSCLC. These findings may have an influence on expanding the inclusion criteria for patients suitable for VATS, especially those candidates who are considered to be too frail for open thoracotomy. In our multi-institutional experience, more than 400 patients with Stage III or IV disease underwent VATS during a period of 8 years. Our preliminary analysis indicates no significant difference in overall survival between VATS and open thoracotomy groups, with a conversion rate of approximately 5% in the cohort of patients with advanced-stage NSCLC. Results presented by Hennon and data from our experience suggest that selected patients with advanced stage NSCLC can undergo VATS resection with acceptable perioperative and long-term outcomes.
